medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2009, Number 4

<< Back Next >>

Arch Neurocien 2009; 14 (4)

Trazodone, an atypical antidepressant with anxiolytic and sedative properties

Alcántara-López MG, Gutiérrez-García AG, Hernández- Lozano M, Contreras CM

Language: Spanish
References: 113
Page: 249-257
PDF size: 145.08 Kb.


ABSTRACT

Trazodone is a second generation, atypical antidepressant. It exerts selective inhibitory actions on the transport of serotonin (5-HT), in a lesser amount than the selective serotonin reuptake inhibitors. The most striking pharmacological effect is as a 5-HT2A and 5- HT2C antagonist. It also blocks the α1 - α2 adrenergic and histamine-1 receptors. It is effective for depression, insomnia treatment and some anxiety disorders, either as monotherapy or in combination with other drugs. Albeit non-conclusive, it is also used as adjunctive therapy in some cases of mania, Tourette syndrome, Alzheimer’s disease and schizophrenia. Trazodone has tried in the erectile dysfunction treatment given its blocking actions on the α-adrenoceptors, but its use is controversial from some reports of priapism. Trazodone has drug interactions with other antidepressants, and some neuroleptics, antimycotics and antiretroviral drugs, among others. The aim of this review is to describe the pharmacology of trazodone and its clinical uses and side effects.


REFERENCES

  1. Ten Have M, de Graaf R, Vollebergh W, Beekman A. What depressive symptoms are associated with the use of care services?. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). J Affect Disord 2004; 80 (2- 3): 239-48.

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4a. Edición. Washington, DC. Ame Psychi Assoc, 2000.

  3. World Health Organization Mental Health. New understanding, new hope. Geneva: World Health Organization, 2001.

  4. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992; 149 (8): 999-1010.

  5. Murray CJL, Lopez AD. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. En: Murray CJL, Lopez AD, editores. The global burden of disease and injury. Vol. 1. Cambridge, Mass: Harvard University Press, 1996.

  6. Silvestrini B, Lisciani R. Pharmacology of trazodone. Curr Ther Res Clin Exp 1973; 15 (10): 749-54.

  7. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50 (11):884-95.

  8. Becker PM. Trazodone as a hypnotic in major depression. Sleep Med 2004; 5 (1):7-8.

  9. Silvestrini B, Cioli V, Burberi S, Catanese B. Pharmacological properties of AF 1161, a new psychotropic drug. Int J Neuropharmacol 1968; 7 (6): 587-99.

  10. Palazzo G. Chemistry of trazodone. Curr Ther Res Clin Exp 1973; 15 (10): 745-8.

  11. Stahl SM. Newer antidepressants and mood stabilizers. En: Stahl SM. Editor. Essential psychopharmacology. Neuroscientific basis and practical applications. Cambridge University Press, 2004.

  12. Coccaro EF, Siever LJ. Second generation antidepressants: a comparative review. J Clin Pharmacol 1985; 25 (4): 241-60.

  13. Bristol-Myers Squibb Company. Información del producto Desyrel® (clorhidrato de trazodona). Princeton, New Jersey. 2003.

  14. Blacker R, Shanks NJ, Chapman N, Davey A. The drug treatment of depression in general practice: a comparison of nocte administration of trazodone with mianserin, dothiepin and amitriptyline. Psychopharmacology (Berl) 1988; 95 Suppl: S18-24.

  15. Weisler RH, Johnston JA, Lineberry CG, Samara B, Branconnier RJ, Billow AA. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994; 14 (3): 170-9.

  16. Munizza C, Olivieri L, Di Loreto G, Dionisio P. A comparative, randomized, double-blind study of trazodone prolongedrelease and sertraline in the treatment of major depressive disorder. Curr Med Res Opin 2006; 22 (9): 1703-13.

  17. Beasley CM Jr, Dornseif BE, Pultz JA, Bosomworth JC, Sayler ME. Fluoxetine versus trazodone: efficacy and activatingsedating effects. J Clin Psychiatry 1991; 52 (7): 294-9.

  18. Feighner JP, Boyer WF. Overview of USA controlled trials of trazodone in clinical depression. Psychopharmacology (Berl) 1988; 95 Suppl: S50-3.

  19. Sánchez Ruiz JC, González López E, Aparicio Tijeras C, Ezquerra Gadea J. Hepatotoxicity due to trazodone. Aten Primaria 2004; 34 (2): 104.

  20. Rettman KS, McClintock C. Hepatotoxicity after short-term trazodone therapy. Ann Pharmacother 2001;35(12):1559-61.

  21. Lin CC, Lin PY, Lee Y, Chang YY, Chen CH. Tardive dystonia and tardive sensory syndrome related to trazodone: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (6): 1609-10.

  22. Balestrieri G, Cerudelli B, Ciaccio S, Rizzoni D. Hyponatraemia and seizure due to overdose of trazodone. BMJ 1992; 304 (6828): 686.

  23. Nilsen OG, Dale O. Single dose pharmacokinetics of trazodone in healthy subjects. Pharmacol Toxicol 1992; 71 (2): 150-3.

  24. Caccia S, Ballabio M, Samanin R, Zanini MG, Garattini S. (-)- m-Chlorophenyl-piperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodone. J Pharm Pharmacol 1981; 33 (7): 477-8.

  25. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Ishida M, et al. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 1995; 17 (4): 333-5.

  26. Ishida M, Otani K, Kaneko S, Ohkubo T, Osanai T, Yasui N, et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite mchlorophe- nylpiperazine. Int Clin Psychopharmacol 1995; 10 (3): 143-6.

  27. Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 1998; 26 (6): 572-5.

  28. Greenblatt DJ, Friedman H, Burstein ES, Scavone JM, Blyden GT, Ochs HR, et al. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther 1987; 42 (2): 193-200.

  29. Aranow AB, Hudson JI, Pope HG Jr, Grady TA, Laage TA, Bell IR, et al. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 1989; 146 (7): 911-3.

  30. Maes M, Westenberg H, Vandoolaeghe E, Demedts P, Wauters A, Neels H, et al. Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of metachlorophenylpiperazine. J Clin Psychopharmacol 1997; 17 (5): 358-64.

  31. Metz A, Shader RI. Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine. Int Clin Psychopharmacol 1990; 5 (3): 191-4.

  32. Zalma A, von Moltke LL, Granda BW, Harmatz JS, Shader RI, Greenblatt DJ. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biol Psychiatry 2000; 47 (7): 655-61.

  33. Bergeron L, Boulé M, Perreault S. Serotonin toxicity associated with concomitant use of linezolid. Ann Pharmacother 2005; 39 (5): 956-61.

  34. Otani K, Ishida M, Kaneko S, Mihara K, Ohkubo T, Osanai T. Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite mchlorophenylpiperazine. Ther Drug Monit 1996; 18 (2): 164-7

  35. Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, Greenblatt DJ. Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin Pharmacol Ther 2009; 85 (6): 644-50.

  36. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352 (11): 1112-20.

  37. Margolese HC, Chouinard G. Serotonin syndrome from addition of low-dose trazodone to nefazodone. Am J Psychiatry 2000; 157 (6): 1022.

  38. Reeves RR, Bullen JA. Serotonin syndrome produced by paroxetine and low-dose trazodone. Psychosomatics 1995; 36 (2): 159-60.

  39. George TP, Godleski LS. Possible serotonin syndrome with trazodone addition to fluoxetine. Biol Psychiatry 1996; 39 (5): 384-5.

  40. Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Baker GB. Metabolism of some «second»- and «fourth»-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol 1999; 19 (4): 427-42.

  41. Stefanini E, Fadda F, Medda L, Gessa GL. Selective inhibition of serotonin uptake by trazodone, a new antidepressant agent. Life Sci 1976; 18 (12): 1459-65.

  42. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997; 283 (3):1305-22.

  43. Kinney GG, Griffith JC, Hudzik TJ. Antidepressant-like effects of 5-hydroxytryptamine1A receptor agonists on operant responding under a response duration differentiation schedule. Behav Pharmacol 1998; 9 (4): 309-18.

  44. Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5- HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol 2005; 19 (3): 235-41.

  45. Akiyoshi J, Tsuchiyama K, Yamada K, Mizobe Y, Nakamura M, Nagayama H. Effect of IAP and chronic antidepressant administration on the 5HT1A receptor in rat cortical membranes. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16(3):339-49.

  46. Tsuchiyama K, Nagayama H, Akiyoshi J, Yamada K, Miyamoto T, Yamauchi C. Effect of chronic administration of trazodone on the 5-HT 1A mediated inhibition of forskolin-stimulated adenylate cyclase activity. Jpn J Psychiatry Neurol 1991; 45 (1): 139-40.

  47. Newman ME, Lerer B, Shapira B. 5-HT-1A receptor mediated effects of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17 (1): 1-19.

  48. Pazzagli M, Giovannini MG, Pepeu G. Trazodone increases extracellular serotonin levels in the frontal cortex rats. Eur J Pharmacol 1999; 383(3): 249-57.

  49. Wander TJ, Nelson A, Okazaki H, Richelson E. Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro. Eur J Pharmacol 1986; 132 (2-3): 115-21.

  50. Marek GJ, Mc Dougle CJ, Price LH, Seiden LS. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl) 1992; 109 (1-2): 2-11.

  51. Golden RN, Dawkins K, Nicholas L, Bebchuk JM. Trazodone, nefazodone, bupropion and mirtazapine. En: Schatzberg AF, Nemeroff CB, editores. The American Psychiatric Press Textbook of Psychopharmacology. Washington DC. Ame Psychi Press 1998; 251-69.

  52. Berendsen HH, Jenck F, Broekkamp CL. Involvement of 5- HT1C-receptors in drug-induced penile erections in rats. Psychopharmacology (Berl) 1990; 101 (1): 57-61.

  53. Millan MJ, Peglion JL, Lavielle G, Perrin-Monneyron S. 5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. Eur J Pharmacol 1997; 325 (1): 9-12.

  54. Clements-Jewery S. The development of cortical betaadrenoceptor subsensitivity in the rat by chronic treatment with trazodone, doxepin and mianserine. Neuropharmacology 1978; 17 (9): 779-81.

  55. Clements-Jewery S, Robson PA, Chidley LJ. Biochemical investigations into the mode of action of trazodone. Neuropharmacology 1980; 19 (12): 1165-73.

  56. Taylor DP, Hyslop DK, Riblet LA. Trazodone, a new nontricyclic antidepressant without anticholinergic activity. Biochem Pharmacol 1980; 29 (15): 2149-50.

  57. El-Fakahany E, Richelson E. Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol 1983; 78(1): 97-102.

  58. Brogden RN, Heel RC, Speight TM, Avery GS. Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs 1981; 21 (6): 401-29.

  59. Pope HG Jr, Keck PE Jr, McElroy SL, Hudson JI. A placebocontrolledstudy of trazodone in bulimia nervosa. J Clin Psychopharmacol 1989; 9 (4): 254-9.

  60. Piggot TA, L´Heureux F, Rubenstein CS, Bernstein SE, Hill JL,Murphy DL. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12 (3): 156-62.

  61. Sultzer DL, Gray KF, Gunay I, Berisford MA, Mahler ME. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997; 5 (1): 60-9.

  62. Ansseau M, De Roeck J. Trazodone in benzodiazepine dependence. J Clin Psychiatry 1993; 54 (5): 189-91.

  63. Charney DS, Woods SW, Goodman WK, Rifkin B, Kinch M, Aiken B, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986; 47 (12): 580-6.

  64. Mavissakalian M, Perel J, Bowler K, Dealy R. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry 1987; 144 (6): 785-7.

  65. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005; 66 (4): 469-76.

  66. Kallepalli BR, Bhatara VS, Fogas BS, Tervo RC, Misra LK. Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders. J. Child Adolesc Psychopharmacol 1997; 7 (2): 97-107.

  67. Scharf MB, Sachais BA. Sleep laboratory evaluation of effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry 1990; 51 Suppl 9: 13-7.

  68. Kaynak H, Kaynak D, Gözükirmizi E, Guilleminault C. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med 2004; 5 (1): 15-20.

  69. Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994; 151 (7): 1069-72.

  70. Ringdahl EN, Pereira SL, Delzell JE Jr. Treatment of primary insomnia. J Am Board Fam Pract 2004; 17(3): 212-9.

  71. Karam-Hage M, Brower KJ. Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients. Psychiatry Clin Neurosci 2003; 57 (5): 542-4.

  72. James SP, Mendelson WB. The use of trazodone as a hypnotic: a critical review. J Clin Psychiatry 2004; 65 (6): 752-5.

  73. Scher M, Krieger JN, Juergens S. Trazodone and priapism. Am J Psychiatry 1983; 140 (10): 1362-3.

  74. Burnett AL. Pathophysiology of priapism: dysregulatory erection physiology thesis. J Urol 2003; 170 (1): 26-34.

  75. Abber JC, Lue TF, Luo JA, Juenemann KP, Tanagho EA. Priapism induced by chlorpromazine and trazodone: mechanism of action. J Urol 1987; 137 (5): 1039-42.

  76. Saenz de Tejada I, Ware JC, Blanco R, Pittard JT, Nadig PW, Azadzoi KM, et al. Pathophysiology of prolonged penile erection associated with trazodone use. J Urol 1991; 145 (1): 60-4.

  77. Brant WO, Garcia MM, Bella AJ, Chi T, Lue TF. T-shaped shunt and intracavernous tunneling for prolonged ischemic priapism. J Urol 2009;181(4):1699-705.

  78. Lance R, Albo M, Costabile RA, Steers WD. Oral trazodone as empirical therapy for erectile dysfunction: a retrospective review. Urology 1995; 46 (1): 117-20.

  79. Krege S, Goepel M, Sperling H, Michel MC. Affinity of trazodone for human penile α1- and α2-adrenoceptors. BJU Int 2000; 85 (7): 959-61.

  80. Eardley I. New oral therapies for the treatment of erectile dysfunction. Br J Urol 1998;

  81. 81 (1): 122-7. 81. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12 Suppl 4: S6-11.

  82. Ugarte y Romano F, Barroso-Aguirre J. Prevalencia de disfunción eréctil en México y factores de riesgo asociados.Revista Mexicana de Urología 2001; 61 (2): 63-76.

  83. Costabile RA, Spevak M. Oral trazodone is not effective therapy for erectile dysfunction: a double-blind, placebo controlled trial. J Urol 1999; 161 (6): 1819-22.

  84. Enzlin P, Vanderschueren D, Bonte L, Vanderborght W, Declercq G, Demyttenaere K. Trazodone: a double-blind, placebo-controlled, randomized study of its effects in patients with erectile dysfunction without major organic findings. Int J Impot Res 2000; 12 (4): 223-8.

  85. Taneja R. A rational combination pharmacotherapy in men with erectile dysfunction who initially failed to oral sildenafil citrate alone: a pilot study. J Sex Med 2007;4(4 Pt 2): 1136-41.

  86. Matarredona J, Pérez E, Bonete JM. Actividad del hidroclorhidrato de trazodona en los trastornos sexuales producidos por los antidepresivos ISRS. Psiq Biol 2005;12 (1):8-13.

  87. Stryjer R, Spivak B, Strous RD, Shiloh R, Harary E, Polak L, et al. Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: A preliminary open-label study. Clin Neuropharmacol 2008. En prensa.

  88. Warner MD, Peabody CA, Whiteford HA, Hollister LE. Trazodone and priapism. J Clin Psychiatry 1987;48(6):244-5.

  89. Thompson JW Jr, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry 1990; 51 (10): 430-3.

  90. Portillo Martín JA, Correas Gómez MA, Gutiérrez Baños JL, Martín García B, Hernández Rodríguez R, del Valle Schaan JI, et al. Incidence of priapism at the Marqués de Valdecilla University Hospital in Santander. Arch Esp Urol 2001; 54 (3): 241-6.

  91. Correas Gómez MA, Portillo Martín JA, Martín García B, Hernández Rodríguez R, Gutiérrez Baños JL, del Valle Shaan JI, et al. Trazodone-induced priapism. Actas Urol Esp 2000;24 (10): 840-2.

  92. Pescatori ES, Engelman JC, Davis G, Goldstein I. Priapism of the clitoris: a case report following trazodone use. J Urol 1993; 149 (6): 1557-9.

  93. Medina CA. Clitoral priapism: a rare condition presenting as a cause of vulvar pain. Obstet Gynecol 2002;100(5 Pt 2):1089-91.

  94. Nayeem K, O´Keeffe S. Delirium. Clin Med 2003; 3 (5):412-5.

  95. Saccomani L, Rizzo P, Nobili L. Combined treatment with haloperidol and trazodone in patients with tic disorders. J Child Adolesc Psychopharmacol 2000; 10 (4): 307-10.

  96. Hayashi T, Yokota N, Takahashi T, Tawara Y, Nishikawa T, Yano T. Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. Int Clin Psychopharmacol 1997;12 (4): 199-205.

  97. Kaneda Y. Successful treatment with trazodone for repetitive behavior in schizophrenia. Nord J Psychiatry 2001;55 (6):448.

  98. Lebert F, Pasquier F, Petit H. Behavioral effects of trazodone in Alzheimer´s disease. J Clin Psychiatry 1994; 55 (12): 536-8.

  99. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55 (9): 1271-8.

  100. Kitamura Y, Kudo Y, Imamura T. Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer’s disease: a retrospective study focused on the aggression and negativism in caregiving situations. No To Shinkei 2006; 58 (6): 483-8.

  101. Martinon-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev 2004; (4): CD004990.

  102. Rascati K. Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/ sleep medications. Clin Ther 1995; 17 (4): 786-90.

  103. Heinze G, Escalante CA, Fernández LR, Galli E, León AC, Moreno RA, et al. The coexistence of depression and anxiety. Salud Mental 1999; 22 (3): 1-4.

  104. Baldessarini RJ. Fármacos y tratamiento para trastornos psiquiátricos. En: Hardman JG, Limbird LE, editores. Las bases farmacológicas de la terapéutica. México: McGraw-Hill, 2003: 455-91.

  105. Al-Yassiri MM, Bridges PK. Trazodone efficacy and safety in endogenous depression: a double blind comparison with imipramine. Neuropharmacol 1980; 19 (12): 1191-3.

  106. Murphy JE, Ankier SI. An evaluation of trazodone in the treatment of depression. Neuropharmacology 1980;19(12): 1217-8.

  107. Pierce D. A comparison of trazodone and dothiepin in depression. Neuropharmacology 1980; 19 (12): 1219-20.

  108. Al-Yassiri MM, Ankier SI, Bridges PK. A double blind comparison of the efficacy and safety of trazodone and imipramine in endogenous depression. J Affect Disord 1983; 5 (4): 333-40.

  109. Magni G, Arsie D, De Leo D. Antidepressants in the treatment of cancer pain. A survey in Italy. Pain 1987; 29 (3): 347-53.

  110. Fudge JL, Perry PJ, Garvey MJ, Kelly MW. A comparison of the effect of fluoxetine and trazodone on the cognitive functioning of depressed outpatients. J Affect Disord 1990; 18 (4): 275-80.

  111. Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996; 41 (3): 201-10.

  112. Rosenthal J, Hemlock C, Hellerstein DJ, Yanowitch P, Kasch K, Schupak C, et al. A preliminary study of serotonergic antidepressants in treatment of dysthymia. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16 (6): 933-41.

  113. Ankier SI, Martin BK, Rogers MS, Carpenter PK, Graham C. Trazodone-a new assay procedure and some pharmacokinetic parameters. Br J Clin Pharmacol 1981;11(5):505-9.




2020     |     www.medigraphic.com